Physician

Sarah Jean Conlon, MD

According to 2025 Medicare claims, Sarah Conlon, MD (NPI: 1861425829) practices hematology/oncology in the Flagstaff, AZ market, with the plurality of this provider's patient population coming from Coconino, AZ. This provider's primary affiliated billing organization is ARIZONA ONCOLOGY ASSOCIATES PC (NPI: 1578587671; TIN: 860938204) and primary practice location at 86001-9998. Conlon is affiliated with the Banner Health Network (ACO ID: A3229) and Equality Health ACO, LLC (ACO ID: A5515), participating under the MSSP model.

Conlon's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 470 traditional Medicare patients, billed 146,847 HCPCS/CPT codes, and received $3,216,533 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,498 prescription claims across 187 beneficiaries totaling $3,205,534 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 29 claims. Open Payments data shows 67 records totaling $1,572. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $20,838 to $3,216,533. Similarly, Part D prescription costs have moved sharply higher in recent years, from $377,141 to $3,205,534. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	134	364	$20,838
2016	135	350	$18,996
2017	243	10,977	$229,546
2018	325	921	$57,446
2019	289	975	$58,432
2020	314	916	$55,805
2021	262	933	$79,099
2022	526	43,466	$973,858
2023	497	106,202	$2,076,435
2024	470	146,847	$3,216,533

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	105	543	$377,141
2016	102	646	$473,997
2017	128	570	$575,092
2018	156	774	$591,399
2019	164	753	$729,975
2020	183	988	$1,347,269
2021	179	789	$1,205,183
2022	161	729	$1,349,189
2023	138	865	$1,995,549
2024	187	1,498	$3,205,534

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$2,944
2020	N/R	N/R	N/R
2021	N/R	66	$4,369
2022	N/R	N/R	N/R
2023	N/R	11	$207
2024	N/R	29	$769

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	97	378	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	271	1,126	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	88	128	$56
36415	Insertion of needle into vein for collection of blood sample	203	387	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	192	359	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	16	448	$369,680
Ibrance	Palbociclib	23	644	$357,077
Xtandi	Enzalutamide	29	870	$333,869
Jakafi	Ruxolitinib Phosphate	21	630	$330,521
Venclexta	Venetoclax	21	626	$299,511

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$505
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	66	$1,572	Genmab U.S., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$303,812	Vektor Medical Inc.

Explore More Providers

FAQ

What Medicare data is available for Sarah Jean Conlon, MD?

Tedicare shows public-source Medicare data for Sarah Jean Conlon, MD (NPI 1861425829), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sarah Jean Conlon, MD have ACO affiliation data?

Sarah Jean Conlon, MD is shown with ACO affiliation data for Banner Health Network (MSSP, ACO ID A3229) and Equality Health ACO, LLC (MSSP, ACO ID A5515).

What billing organization is linked to Sarah Jean Conlon, MD?

Sarah Jean Conlon, MD is linked to ARIZONA ONCOLOGY ASSOCIATES PC (billing NPI 1578587671) in the available physician profile data.

Does Sarah Jean Conlon, MD have Open Payments data?

Sarah Jean Conlon, MD has 67 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.